Leerink Partners Rates Altimmune (ALT) buy, $10 Price Target

Leerink Partners reaffirms its optimistic outlook for Altimmune, Inc. with a $10 price target, a 236.56% upside from the current price.

By EarningsIQ Research Desk · Published Jun 22, 2026, 10:02 PM EDT · Updated Jun 25, 2026, 12:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Leerink Partners rated Altimmune, Inc. ($ALT) "buy" with a $10 price target on June 22, 2026.

Since the rating, $ALT is up 0.3% after 1 week, down 4.1% after 1 month and down 24.9% to date (from the $2.93 close on Jun 22, 2026).

ALT Altimmune, Inc.

$2.20 -37.32% year to date

Daily close · Oct 16, 2026

Key Points

Leerink Partners reiterated its buy rating on Altimmune, Inc. (ALT) with a $10 price target on June 22, 2026.
Leerink Partners's $10 price target implies 236.56% upside from Altimmune, Inc.'s ($ALT) current $2.97 share price.
Altimmune, Inc. traded near $2.95 on Tuesday, with a market cap of about $569.8 million and a 52-week range between $2.56 and $7.73.
Insiders recently bought shares, and other analysts like HC Wainwright & Co. and Citizens also maintain buy ratings with higher targets.

Get $ALT trade alerts by text

We text you when insiders, Congress or big funds trade $ALT. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Altimmune, Inc. alert may contain errors. Disclosures

On June 22, 2026, Leerink Partners reiterated its buy rating on Altimmune, Inc. (NasdaqGM: ALT) with a price target of $10. Analyst Thomas Smith expressed continued optimism about the company's prospects.

Analyst rating track record

Leerink Partners vs. the S&P 500

YTD return +41.02% hypothetical

All-time return +41.02% S&P 500 +7.82%

vs. S&P 500 +33.20% ahead of the index

Hypothetical returns from Leerink Partners's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Altimmune, Inc.

Several major institutional investors have shown interest in Altimmune. BlackRock, Inc. increased its holdings by 3,090,979 shares, bringing its total to 12,795,277 shares, valued at approximately $39.4 million. State Street Corp added 2,025,847 shares, now holding 7,145,550 shares worth about $22 million. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions, acquiring 5,658,049 and 5,382,002 shares, respectively. Marshall Wace, LLP significantly boosted its stake by 3,095,124 shares, totaling 4,017,901 shares valued at around $12.4 million.

Altimmune, Inc. Stock Down 8.6%

Shares of Altimmune, Inc. traded near $2.95 on Tuesday. The company has a market cap of approximately $569.8 million. Its forward P/E ratio is not meaningful as the company isn't profitable, and it has a beta of 0.234, indicating low volatility. Over the past year, the stock has ranged between $2.56 and $7.73. The 50-day moving average is $2.96, while the 200-day moving average is $3.89. Altimmune maintains a strong liquidity position with a current ratio of 29.56 and a quick ratio of 29.43, alongside a debt-to-equity ratio of 12.62.

12-month forecast

$ALT price target

Altimmune, Inc. daily closes and this analyst's $10 target. Not advice.

Insider Buying and Selling at Altimmune, Inc.

Several insiders at Altimmune, Inc. made purchases on May 1, 2026. John Gill, Diane Jorkasky, Teri Lawver, Wayne Pisano, Philip Hodges, and Catherine Sohn each bought 48,800 shares. These transactions were not part of a pre-arranged trading plan.

Analysts Set New Price Targets

On June 22, 2026, Leerink Partners reiterated its buy rating for Altimmune, Inc. with a $10 price target. HC Wainwright & Co. maintained its buy rating with a higher target of $20 on May 18, 2026. Citizens also reiterated a buy rating with an $11 target on May 14, 2026. The consensus among nine analysts is a buy recommendation, with an average target price of $16.06.

About Altimmune, Inc.

Altimmune, Inc. is a biotechnology company based in Gaithersburg, Maryland. It focuses on developing treatments for serious liver diseases. Its lead product, pemvidutide, is in Phase 3 trials for various liver-related conditions. Founded in 1997, the company is led by CEO Jerome Benedict Durso and employs 57 people.

Bottom Line

Leerink Partners' reiterated buy rating and $10 target for Altimmune, Inc. reflect ongoing confidence in the company's potential. Investors track these updates as part of analyzing the stock's future trajectory. Remember, analyst ratings are opinions and should be considered in the context of broader research.